Pharmaceutical formulations of poorly water soluble camptothecin analogues and NMP
US5958937A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 22, 1997 |
| Grant date | Sep 28, 1999 |
| Priority date | — |
| Expiry date | Oct 22, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A- and/or B-ring substituted camptothecin derivatives, which are poorly water soluble (less than 5 micrograms per milliliter of water), are highly lipophilic camptothecin derivatives (HLCD) and are very active against a variety of human cancers. Because of their very poor water solubility, HLCD have not been used to treat human patients with cancer due to the inability to administer sufficient quantities of the HLCD dissolved in a pharmaceutical formulation. This invention overcomes these limitations by teaching novel pharmaceutically acceptable HLCD formulations for the direct administration of HLCD to human patients with cancer. The claimed invention also describes the methods to create solutions of HLCD and antitumor compositions of HLCD to allow the administration of HLCD in sufficient amounts to treat human patients with various types of cancer. This invention is also directed to injectable sterile solutions, antitumor compositions, solutions and suspensions comprising N-methyl-2-pyrrolidinone and a highly lipophilic camptothecin derivative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.